Immunocellular Therapeutics, Ltd. (NYSE: IMUC) reported Q2 EPS of $0.04, $0.10 better than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Immunocellular Therapeutics, Ltd. (IMUC) click here.